Other languages Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-01 EDT			5-day change	1st Jan Change
3.285 ^USD	+6.66%		+28.82%	-33.64%

04-08	Genenta Science S.P.A. Announces Resignation of Board Members	CI
03-29	Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Genenta Science S.P.A. Announces Resignation of Board Members	04-08
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29
Genenta Science Demonstrated Reprogramming of the Tumor Microenvironment in Gbm Patients, Paving the Way for Innovative Treatments of Solid Tumors	02-08
Sandoz kauft Medikament Cimerli für 170 Millionen US-Dollar von Coherus	01-22
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2023	23-10-20
Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments	23-07-28
Health Care Stocks Support American Depositary Receipts of European Equities	23-06-16
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-21
Genenta Science S.p.A. Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications	23-04-03
Genenta Science Says Temferon Receives US FDA's Orphan Drug Designation for Treatment of Glioblastoma Multiforme	23-03-02
FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme	23-03-02
Genenta Science Signs Development, Manufacturing Deal With AGC Biologics	23-02-07
Genenta Science S.P.A. and Ospedale San Raffaele S.R.L. Enters into License Agreement	22-12-22
Genenta Science S.p.A. Reports Earnings Results for the Half Year Ended June 30, 2022	22-10-25
Genenta Science S.p.A Shares Plunge After HC Wainwright Initiates Coverage	22-07-25
European ADRs Move Higher in Tuesday Trading	22-05-17
European ADRs Decline in Wednesday Trading	22-05-04
Genenta Science S.P.A. Announces Ongoing Trial of Temferon™	22-05-04
Genenta Science Announces Preliminary Findings from its Phase 1/2A of Temferon™ in the Treatment of Patients with Glioblastoma	22-05-02
Genenta Science S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2021	22-05-02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Genenta Science S.p.A.

Equities

GNTA

US36870W1009

Other languages

Filters